PUBLIC COMPANY
save$KYMRKymera Therapeutics, Inc.
$KYMR121.19+0.05%Watertown, MA, USupdated 1h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
- phase2A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
- phase2A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
- phase1First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
- phase1Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
- phase1First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
- phase1Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
- phase1Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
🐶 Hiring Signal
Where Kymera Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaImmunology & Inflammation 21
News
- Sanofi stops development of Nurix-partnered immune drugThe decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.biopharma_dive · 15d ago
- STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival DupixentInvestors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.stat · 17d ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 1mo ago
- North Immunology joins biotech reverse merger boom with Aethlon dealArmed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.biopharma_dive · 2mo ago
- Chutes & Ladders—Legend CEO departs without successor in placeLegend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…fiercebiotech · 3mo ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that